{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T04:25:11Z","timestamp":1770956711756,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jpba.2020.113109","type":"journal-article","created":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T14:05:47Z","timestamp":1579010747000},"page":"113109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma"],"prefix":"10.1016","volume":"181","author":[{"given":"Filipa","family":"Gouveia","sequence":"first","affiliation":[]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Mar\u00edlia","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2020.113109_bib0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(15)60245-8","article-title":"Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs","volume":"386","author":"Verheugt","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2020.113109_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2017.02.001","article-title":"Old and new oral anticoagulants: food, herbal medicines and drug interactions","volume":"31","author":"Di Minno","year":"2017","journal-title":"Blood Rev."},{"key":"10.1016\/j.jpba.2020.113109_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ejhpharm-2017-001390","article-title":"Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban","author":"Garbayo","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"key":"10.1016\/j.jpba.2020.113109_bib0020","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/europace\/euv124","article-title":"Non-Vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.jpba.2020.113109_bib0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/jth.12086","article-title":"Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation?","volume":"11","author":"Rodriguez","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.jpba.2020.113109_bib0030","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/europace\/euy054","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary","author":"Steffel","year":"2018","journal-title":"Europace"},{"key":"10.1016\/j.jpba.2020.113109_bib0035","first-page":"1","article-title":"New oral anticoagulants : discussion on monitoring and adherence should start now !","volume":"11","author":"Cate","year":"2013","journal-title":"Thromb. J."},{"key":"10.1016\/j.jpba.2020.113109_bib0040","article-title":"Impact of direct oral anticoagulants off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review","author":"Santos","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2020.113109_bib0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/clc.22591","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and renal impairment, extremes in weight, or advanced age","volume":"40","author":"Buckley","year":"2017","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.jpba.2020.113109_bib0050","doi-asserted-by":"crossref","first-page":"0","DOI":"10.1111\/eci.12907","article-title":"Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation","volume":"48","author":"Andreu Cayuelas","year":"2018","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.jpba.2020.113109_bib0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.aca.2019.03.061","article-title":"Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: a critical review","volume":"1076","author":"Gouveia","year":"2019","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2020.113109_bib0060","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1515\/cclm-2016-0888","article-title":"Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS\/MS","volume":"55","author":"Wiesen","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2020.113109_bib0065","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jpba.2017.10.011","article-title":"Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy","volume":"148","author":"Foerster","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113109_bib0070","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/FTD.0000000000000059","article-title":"Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry","volume":"36","author":"Gous","year":"2014","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2020.113109_bib0075","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.jpba.2020.113109_bib0080","series-title":"ICH Guideline M10 on Bioanalytical Method Validation","author":"European Medicines Agency","year":"2019"},{"key":"10.1016\/j.jpba.2020.113109_bib0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","article-title":"Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods","volume":"774","author":"Almeida","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2020.113109_bib0090","first-page":"136","article-title":"Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Off. J. Int. Soc. Nephrol."},{"key":"10.1016\/j.jpba.2020.113109_bib0095","first-page":"5442","article-title":"Update of standard practices for new method validation in forensic toxicology","volume":"23","author":"Willie","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jpba.2020.113109_bib0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/2229-4708.72226","article-title":"Bioanalytical method validation: an updated review","volume":"1","author":"Tiwari","year":"2010","journal-title":"Pharm. Methods"},{"key":"10.1016\/j.jpba.2020.113109_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0731-7085(97)00198-2","article-title":"Validation of bioanalytical chromatographic methods","volume":"17","author":"Hartmann","year":"1998","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2020.113109_bib0110","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/FTD.0000000000000355","article-title":"Development of an UHPLC-UV-Method for quantification of direct oral anticoagulants","volume":"39","author":"Boehr","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2020.113109_bib0115","first-page":"216","article-title":"Determination of rivaroxaban in human plasma by solid-phase extraction-high performance liquid chromatography","volume":"54","author":"\u00c7elebier","year":"2016","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2020.113109_bib0120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2020.113109_bib0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.thromres.2017.05.005","article-title":"Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay","volume":"155","author":"He","year":"2017","journal-title":"Thromb. Res."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519330456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708519330456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:00:10Z","timestamp":1760000410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708519330456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"alternative-id":["S0731708519330456"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113109","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development, validation and application of a new HPLC-DAD method for simultaneous quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2020.113109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113109"}}